IP Library Granted Patent US 7,364,727
Granted Patent B2
US 7,364,727 · App. 10/624,670 · Granted Apr 29, 2008

Metastatic colon cancer specific promoter and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,364,727
App. No.
10/624,670
Granted
Apr 29, 2008
Kind
B2
Abstract

Colon cancer specific promoter sequences and adenovirus vehicles are provided. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.

Claims (13)

1. A replication-competent adenovirus vector comprising an adenovirus gene essential for replication under transcriptional control of a sequence comprising SEQ ID NO:1.

2. The adenovirus vector according to claim 1 , wherein said sequence comprises a human promoter or enhancer.

3. The adenovirus vector according to claim 1 , wherein said sequence comprises a second human transcriptional regulatory factor response element.

4. The adenovirus vector according to claim 1 , wherein said sequence comprises a promoter and enhancer.

5. The adenovirus vector according to claim 1 , wherein said sequence comprises two or more enhancers.

6. The adenovirus vector according to claim 1 , wherein the adenoviral vector comprises first and second adenoviral genes co-transcribed under transcriptional control of said sequence.

7. The adenovirus vector according to claim 6 , wherein the second gene is under translational control of an internal ribosome entry site (IRES).

8. The adenovirus vector according to claim 1 , wherein said adenoviral gene essential for replication is E1A or E1B.

9. The adenovirus vector of claim 8 , wherein E1A or E1B has a mutation in or deletion of its endogenous promoter.

10. The adenovirus vector of claim 9 , wherein E1B has a deletion of the 19-kDa region.

11. A composition comprising:

a replication-competent adenovirus vector according to claim 1 and a pharmaceutically acceptable excipient.

12. An isolated host cell comprising the adenovirus vector of claim 1 .

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME, PREVIOUSLY RECORDED AT REEL 014076, FRAME 0763. Recorded Mar 3, 2004
From: LI, YUANHAO; YU, DE-CHAO
To: CELL GENESYS, INC.
Reel/Frame 015067/0734 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2003
From: LI, YUANHO; YU, DE-CHAO
To: CELL GENESYS, INC.
Reel/Frame 014076/0763 →